Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Adverum Biotechnologies Inc (NASDAQ: ADVM) closed at $9.53 up 3.70% from its previous closing price of $9.19. In other words, the price has increased by $3.70 from its previous closing price. On the day, 0.81 million shares were traded. ADVM stock price reached its highest trading level at $9.964 during the session, while it also had its lowest trading level at $8.76.
Ratios:
For a deeper understanding of Adverum Biotechnologies Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.13 and its Current Ratio is at 4.13. In the meantime, Its Debt-to-Equity ratio is 0.90 whereas as Long-Term Debt/Eq ratio is at 0.77.
SVB Leerink Downgraded its Outperform to Mkt Perform on May 03, 2021, while the target price for the stock was maintained at $5.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 07 ’24 when Lupher, Jr. Mark L. bought 130,000 shares for $1.35 per share. The transaction valued at 175,500 led to the insider holds 130,000 shares of the business.
Scopa James Paul bought 100,000 shares of ADVM for $135,000 on Feb 07 ’24. The Director now owns 100,000 shares after completing the transaction at $1.35 per share. On Sep 15 ’23, another insider, Seyedkazemi Setareh, who serves as the Chief Development Officer of the company, sold 6,201 shares for $1.52 each. As a result, the insider received 9,429 and left with 47,674 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADVM now has a Market Capitalization of 197794192 and an Enterprise Value of 176304336. For the stock, the TTM Price-to-Sale (P/S) ratio is 54.93 while its Price-to-Book (P/B) ratio in mrq is 1.16. Its current Enterprise Value per Revenue stands at 48.973 whereas that against EBITDA is -1.493.
Stock Price History:
The Beta on a monthly basis for ADVM is 0.87, which has changed by 0.27066672 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, ADVM has reached a high of $29.70, while it has fallen to a 52-week low of $7.10. The 50-Day Moving Average of the stock is -38.56%, while the 200-Day Moving Average is calculated to be -30.60%.
Shares Statistics:
For the past three months, ADVM has traded an average of 309.05K shares per day and 370700 over the past ten days. A total of 20.75M shares are outstanding, with a floating share count of 14.98M. Insiders hold about 27.84% of the company’s shares, while institutions hold 36.76% stake in the company. Shares short for ADVM as of 1713139200 were 1130658 with a Short Ratio of 3.66, compared to 1710460800 on 648483. Therefore, it implies a Short% of Shares Outstanding of 1130658 and a Short% of Float of 5.6700002.
Earnings Estimates
The stock of Adverum Biotechnologies Inc (ADVM) is currently in the spotlight, with 5.0 analysts actively rating and assessing its market standing.On average, analysts expect EPS of -$1.41 for the current quarter, with a high estimate of -$1.2 and a low estimate of -$1.91, while EPS last year was -$2.9. The consensus estimate for the next quarter is -$1.31, with high estimates of -$1.2 and low estimates of -$1.48.
Analysts are recommending an EPS of between -$4.8 and -$6.01 for the fiscal current year, implying an average EPS of -$5.41. EPS for the following year is -$5.43, with 5.0 analysts recommending between -$4.9 and -$6.0.
